GLP-1 Prior Authorization: The Exact Requirements (and How to Meet Them)

You finally have a prescription for Wegovy or Zepbound — and then your insurance sends back a prior authorization request that looks like a legal brief.

We get it. The criteria are buried in plan documents, the language is clinical, and one missing piece of paperwork can mean a flat denial.

Here's the good news: prior authorization criteria for GLP-1 drugs follow a predictable pattern — and when you know exactly what insurers are looking for, you can help your prescriber build a bulletproof submission.

Specifically, you'll learn: the exact BMI and comorbidity thresholds most plans use, what "step therapy" actually means in practice, the documentation that makes or breaks a submission, why denials happen (and which ones are worth fighting), and what to do when the PA fails entirely.

Why GLP-1 Prior Authorization Is So Complicated

Most insurance prior authorizations are straightforward: your doctor documents a diagnosis, the plan checks a box, and the drug gets approved.

GLP-1 weight-loss coverage doesn't work that way.

The core problem is that many insurance plans — including most employer plans and standard Medicare — treat weight loss as a lifestyle issue, not a medical one.

That means the PA criteria aren't just about proving you need the drug clinically. They're also about navigating a system that was built, in many cases, to make approval difficult.

Here's the deal:

There are actually two separate battles in a GLP-1 prior auth. First, you have to clear the clinical criteria (BMI, comorbidities, lifestyle documentation). Second, the drug has to be a covered benefit in the first place.

If your plan excludes anti-obesity medications as a category — which is surprisingly common — no amount of perfect documentation will flip that decision. We'll cover how to tell the difference in Section 4.

For now, let's focus on what you can control: making sure every clinical criterion is documented completely before the submission goes in.

The Core PA Criteria — Line by Line

Most commercial insurance plans that do cover GLP-1s for weight loss use a version of the same core criteria.

They won't always use identical language, but the underlying requirements are consistent enough that you can prepare for all of them at once.

Criterion 1: A Qualifying BMI

This is the starting gate for almost every GLP-1 PA — and the threshold is more nuanced than most people realize.

• BMI ≥ 30 (clinical obesity) — qualifies on its own in most plans
• BMI ≥ 27 (overweight) — qualifies only if you also have at least one weight-related comorbidity

The comorbidities that most plans accept alongside a BMI of 27–29.9 include: hypertension, type 2 diabetes, dyslipidemia (high cholesterol/triglycerides), obstructive sleep apnea, and cardiovascular disease.

For a deeper dive on the BMI thresholds by plan type, see our companion piece: What BMI Do You Need for GLP-1 Coverage? The Real Criteria.

The key thing to understand:

Your BMI and any qualifying comorbidities must appear in your chart notes at the time of the PA request — not just in your medical history. A diagnosis from three years ago that hasn't been mentioned recently can be invisible to a reviewer.

Ask your prescriber to document your current BMI measurement and any active comorbidities explicitly in the visit note tied to the PA.

Criterion 2: Documented Diet and Lifestyle Participation

Most plans require evidence that you've already been trying to manage your weight through diet and increased physical activity — typically for three to six months before the PA is submitted.

This doesn't mean you failed a formal program. It means your chart should show a pattern: a clinician discussing weight management, dietary changes, activity goals, and follow-up visits.

If your records don't have that thread, ask your prescriber what they can document from your visit history — and consider scheduling a dedicated weight-management visit before the PA goes in.

Criterion 3: FDA-Approved Indication Match

The drug you're requesting has to be approved for the use you're requesting it for.

Wegovy, Zepbound, Wegovy Pill (oral semaglutide), and Foundayo are FDA-approved for weight management in adults with obesity or overweight with comorbidities.

Ozempic and Mounjaro are FDA-approved for type 2 diabetes — not weight loss. Requesting either of those drugs under a weight-loss PA is almost always rejected for off-label use. (More on how to frame diabetes cases correctly in Section 6.)

Criterion 4: Prescriber Attestation

Your prescriber — whether that's a primary care doctor, endocrinologist, or obesity medicine specialist — typically needs to sign a formal attestation stating that you meet the criteria and that the drug is medically necessary.

Many PA denials happen not because the clinical facts are wrong, but because the attestation form is incomplete or the documentation in the chart doesn't match what the prescriber attested to.

Step Therapy: What Plans Actually Require

Step therapy — sometimes called "fail first" — is when a plan requires you to try a cheaper or preferred medication before they'll approve the one your doctor actually prescribed.

In the GLP-1 space, this shows up in a few different ways.

Preferred vs. Non-Preferred GLP-1s

If your plan covers GLP-1s for weight loss, it likely has one or two drugs on the preferred tier and others on a non-preferred or specialty tier.

If your doctor wrote for Zepbound but the plan prefers Wegovy, you may need to try Wegovy first — or document why Zepbound is medically necessary for you specifically.

Check your plan's formulary (it's usually available in your insurance portal or by calling the pharmacy benefits number) before the PA is submitted, so your prescriber can request the right drug — or justify the exception upfront.

Older Weight-Loss Medications

Some plans require a trial of an older, generic weight-loss medication — such as phentermine or orlistat — before approving a GLP-1.

If you've tried one of these in the past and it was ineffective or not tolerated, that history needs to be in your chart. Verbal history isn't enough; the prescriber needs to document it.

Bottom line:

Step therapy requirements vary widely by plan. Some plans have none; others require a full documented trial. The only way to know is to pull the actual PA criteria from your specific plan — your prescriber's office can often request this directly from the plan's pharmacy or medical director.

The Most Common Denial Reasons (and Which Ones to Fight)

A GLP-1 PA denial is not the end of the road — but your next move depends entirely on why you were denied.

There are two fundamentally different types of denials, and they require completely different responses.

Type 1: Clinical Denials (Worth Fighting)

A clinical denial means the plan agrees weight-loss drugs are a covered benefit — but says your specific documentation didn't meet their criteria. These are worth appealing because the benefit exists.

Common clinical denial reasons include:

• BMI or comorbidity not recorded in the chart at the time of the request
• Step therapy not completed, or completed but not documented
• Diet and lifestyle participation not sufficiently documented
• Prescriber attestation was incomplete or didn't reference the plan's specific criteria
• Wrong drug requested — a diabetes-only drug submitted under a weight-loss PA

All of these are fixable with the right documentation. See Section 5 for the appeal process.

Type 2: Benefit Exclusion Denials (Pivot Instead)

A benefit exclusion denial means your plan doesn't cover anti-obesity medications at all — it's a plan design decision, not a clinical one.

Many employer-sponsored plans and standard Medicare carve out weight-loss drugs entirely. This is unfortunately common.

Here's the hard truth:

When a plan excludes weight-loss drugs as a benefit category, internal appeals rarely succeed. An external review organization can sometimes distinguish between a medical necessity and a benefit exclusion, but the odds are lower than with a clinical denial.

In these cases, your energy is better spent pivoting: to a covered indication (see Section 6), to a cash-pay option (see Section 7), or — if you're on Medicare — to the new GLP-1 Bridge program starting July 1, 2026.

For a detailed walkthrough of the Wegovy-specific denial process, see: Wegovy Prior Authorization Denied? How to Overturn It (2026).

The Appeal Ladder: Your Step-by-Step Path

If you have a clinical denial — or even a questionable benefit exclusion — here's the sequence of escalations available to you.

Step 1: Internal Appeal #1 — Letter of Medical Necessity

This is your first formal challenge. Your prescriber submits a detailed letter that ties your documented medical record to each criterion the plan named in the denial.

Generic letters don't work. The letter needs to reference the plan's own PA criteria by name and show, point by point, how the chart documentation satisfies each one.

Step 2: Peer-to-Peer Review

Your prescriber requests a direct phone call with the plan's medical director.

This step is underused and often highly effective for clinical denials. A physician speaking clinician-to-clinician — with the chart in front of them — can resolve documentation disputes that a paper appeal can't.

Your prescriber's office needs to request this specifically; plans are required to offer it but won't always volunteer it.

Step 3: Internal Appeal #2

If new documentation has become available — a new diagnosis, updated chart notes, additional lifestyle program records — a second internal appeal can incorporate it.

This step is most useful when new information genuinely changes the picture, not just as a delay tactic.

Step 4: External Review

An independent review organization — a neutral third party with no financial relationship to your insurer — reviews the denial.

External review is where benefit-exclusion-vs.-medical-necessity arguments sometimes get resolved differently than they did internally. If your plan is denying a drug with a clear FDA indication on medical necessity grounds, external review is worth pursuing.

Most states require insurers to follow external review decisions. Your denial letter must include instructions for requesting external review.

For the full step-by-step appeal guide, visit our appeal resource center.

Coverage Angles Most People Miss

Sometimes the best strategy isn't fighting the weight-loss PA — it's reframing the request around a different covered indication entirely.

This changes everything:

Two of the most powerful reframing opportunities are widely underused.

Wegovy's Cardiovascular Indication

Wegovy carries an FDA indication specifically to reduce cardiovascular risk in adults with established cardiovascular disease and obesity or overweight — not just for weight loss.

If you have a documented history of heart disease, a PA framed around cardiovascular risk reduction is a completely different clinical request than one framed around weight management. Many plans that exclude weight-loss drugs still cover cardiovascular medications.

Your prescriber needs to frame the letter of medical necessity around the cardiovascular indication, not weight loss, and your chart needs to document the qualifying cardiovascular diagnosis.

Diabetes Coverage for Ozempic and Mounjaro

GLP-1 coverage for type 2 diabetes is far more consistent than weight-loss coverage — covered by commercial insurance, Medicare Part D, and Medicaid in nearly every state.

If you have a type 2 diabetes diagnosis, the appropriate drug request is Ozempic or Mounjaro (the diabetes-approved versions of semaglutide and tirzepatide), submitted under a diabetes PA — not a weight-loss PA.

This isn't a workaround; it's the correct clinical framing. The key is that the diagnosis has to be real and documented.

Comorbidities That Move BMI-27 Patients Into Coverage

If your BMI is in the 27–29.9 range, a single documented comorbidity — hypertension, dyslipidemia, prediabetes, sleep apnea — is often all that's needed to qualify under the lower BMI threshold.

Many patients have these conditions and don't realize they're relevant to the PA. Make sure your prescriber reviews your full problem list before submission.

For a detailed look at Zepbound coverage specifically, see: How to Get Zepbound Covered by Insurance in 2026.

When the PA Fails: Your Cash-Pay Backup Plan

Sometimes the insurance path doesn't work — at least not right now. That doesn't mean you're stuck paying full list price.

There are legitimate, manufacturer-backed cash-pay options that bring monthly costs down significantly (all figures as of June 2026 — verify current pricing before you commit).

One important caveat:

Manufacturer savings cards — the ones that bring costs to $25 or $0/month — generally require commercial insurance and exclude Medicare, Medicaid, and Tricare. That exclusion is the number one reason a savings card "doesn't work" for someone who tries to use it.

If you're on Medicare, the new GLP-1 Bridge program (starting July 1, 2026) is the first path to GLP-1 weight-loss coverage for some Part D members at approximately $50/month. It's a limited, time-bound demonstration — not permanent coverage — and not every plan or person qualifies. Visit our Medicare Bridge guide for eligibility details.

If you're on Medicaid, coverage for weight-loss GLP-1s varies sharply by state. Currently, 13 states have confirmed coverage; three states — California, Michigan, and Pennsylvania — are confirmed cutting it in 2026. Coverage for diabetes is available in nearly every state. See our Medicaid coverage tracker for your state.

Your Next Move

Prior authorization for GLP-1 drugs is genuinely complicated — but it follows a predictable logic once you know the criteria, understand why denials happen, and know which levers to pull.

The single most important thing you can do right now is make sure your chart documentation covers every criterion before the PA goes in — BMI, comorbidities, lifestyle participation, and the right drug for the right indication.

If the first PA fails, you have a full appeal ladder available to you, and reframing around cardiovascular or diabetes indications can open doors that a weight-loss PA cannot.

What's your current situation — fighting a denial, preparing a first submission, or trying to figure out a cash-pay backup while the PA is pending?